Press Release

Covidien Launches Two Enhanced LigaSure™ Vessel Sealing Products at American College of Surgeons Clinical Congress 2013

LigaSureTM portfolio celebrates 15th anniversary with redesigned LigaSure Impact™ and LigaSure™ Blunt Tip, offering improved ergonomics for a better surgical experience

MANSFIELD, Mass.--(BUSINESS WIRE)--Oct. 9, 2013-- Covidien (NYSE: COV), a leading global provider of healthcare products, is strengthening its vessel sealing portfolio with the launch of two advanced energy devices, the LigaSure Impact™ curved large jaw open sealer/divider LF4318 and LigaSure™ blunt tip laparoscopic sealer/divider LF1637. The two products offer improvements in handling, control and performance, as compared to their predecessor devices. LigaSure products used with the ForceTriad™ energy platform utilize TissueFect™ sensing technology, a proprietary Covidien control system designed to precisely manage energy delivery, creating a range of options for desired tissue effect.

“Around the world, Covidien’s LigaSure devices are a trusted and valued product portfolio in the operating room. LigaSure vessel sealing instruments already are used in millions of surgical procedures and we continue to innovate to enhance our products,” said Chris Barry, President of Advanced Surgical Technologies, Covidien. “Since introduction in 1998, our LigaSure devices, combined with TissueFect sensing technology, have set the standard in vessel sealing.”

The LigaSure Impact device, featuring a curved, large jaw open sealer/divider, offers improved visibility in the surgical field, more intuitive jaw positioning and enhanced ergonomics for a better surgical experience. The LigaSure blunt tip laparoscopic sealer/divider has contoured tips for improved dissection, better handling and a more compact, ergonomic handle for greater comfort and control for various hand sizes.

Both the LigaSure Impact and blunt tip devices received U.S Food and Drug Administration 510(k) clearance earlier this year and are ideally suited for colorectal, general, gynecologic, urologic and thoracic surgery.

About LigaSure and TissueFect

With more than eight million procedures completed worldwide, LigaSure technology is supported by an ever-growing body of evidence-based research, now totaling well over 300 published peer-reviewed studies.

LigaSure tissue fusion in the ForceTriad energy platform, has faster fusion cycles, more flexible fusion zones and less desiccation than the original LigaSure generator. TissueFect sensing technology monitors changes in tissue 3,333 times a second and adjusts energy output accordingly to deliver the appropriate amount of energy for the desired tissue effect.

About Covidien

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading products in medical devices and supplies. With 2012 revenue of $9.9 billion, Covidien has 38,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.

Source: Covidien

Covidien
John Jordan, 508-452-4891
Manager, Communications
Surgical Solutions
john.jordan@covidien.com
or
Marguerite Copel, 203-821-4720
Vice President, Communications
Surgical Solutions
marguerite.copel@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

X